Breaking

NVIDIA Unveils BioNeMo Agent Toolkit for Drug Discovery at BIO 2026

June 25, 2026 at 12:46 EDT

AI Agents
Healthcare
Foundation Models

On June 23, 2026, at the BIO International Convention (BIO 2026) in San Diego, NVIDIA announced the NVIDIA BioNeMo Agent Toolkit, a domain-specific toolkit that lets AI agents autonomously carry out scientific workflows across biology, chemistry, genomics and drug discovery. Kimberly Powell, NVIDIA's VP of Healthcare, presented the new toolkit on the show floor.

June 23, 2026 · BIO 2026, San Diego · NVIDIA

BioNeMo Agent Toolkit: AI Agents Get a Scientific Toolbox

NVIDIA equips general-purpose AI agents with domain-specific life-science skills — protein structure prediction, molecular docking, generative chemistry, and genomic analysis — so they can autonomously run computational experiments. "Frontier models are the brains; BioNeMo is the scientific toolbox." — Jensen Huang

Benchmark — Task Completion Rate

Before

57.1%

baseline agent

With BioNeMo skills

100%

Codex CLI + GPT-5.5 fast

Full task completion — verified across 830+ controlled runs integrating NIM skills.

~2×

Token efficiency — passing assertions per 1k tokens, on average

2× faster

RosettaFold3 runtime (UW Institute for Protein Design)

~50

Partners — Eli Lilly, Thermo Fisher, Owkin, Natera

The Agentic Loop

Gather evidence

→

Reason

→

Run computational experiment

→

Propose next action

Skills delivered as agent-callable NIM microservices — open and harness-agnostic. Most effective for workflows that chain multiple tools.

Promise

AI agents enter the lab as PhD-level assistants. Iterative design speed has reached a level "impossible for humans." — David Baker, IPD

Open Questions

Real-world wet-lab integration still lies ahead, and verifying agent outputs may become a new bottleneck. Pricing not yet specified; use centers on prototype stages.

Continue reading

The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.